The CEO's Form 144 is part of a pre-arranged 10b5-1 plan, reducing its negative signaling weight. However, the sustained selling pattern (7 insider sales totaling $700K in the last 30 days) warrants monitoring for any acceleration. Watch for any deviation from the plan or increased volume beyond the disclosed amounts.
Price Chart
Executive Summary
CEO Derek Maetzold filed a Form 144 to sell 29,014 shares of Castle Biosciences common stock, valued at approximately $938,022.62, through Goldman Sachs. The sales are part of a 10b5-1 trading plan adopted on June 2, 2026, covering shares acquired via gifts, stock option exercises, and trusts. This is a continuation of a sustained selling pattern by the CEO over the past several months, with recent insider sales totaling $700K in the last 30 days, but the 10b5-1 plan structure reduces the signaling value of the intent to sell.
Key Facts
- CEO Derek Maetzold filed Form 144 to sell 29,014 shares of Castle Biosciences common stock.
- Estimated aggregate market value of the proposed sale is $938,022.62.
- Sales are conducted under a Rule 10b5-1 trading plan dated June 2, 2026.
- The plan covers shares from multiple sources: 17,164 shares by Derek Maetzold, 5,445 shares by DM 2020 Irrev Trust, and 6,405 shares by Maetzold Descendants 2020 Tr.
- Recent insider activity (30d) shows 7 sells totaling $700K, consistent with this pattern.
- The company has a market cap of $987M and analyst consensus is 93% bullish (14 buys, 1 hold).
Financial Impact
Proposed sale of 29,014 shares valued at ~$938K, representing approximately 0.095% of the company's $987M market cap.
Risk Factors
- CEO's sustained selling pattern could signal lack of confidence if it accelerates beyond the 10b5-1 plan.
- The 10b5-1 plan covers shares from trusts and option exercises, which may create overhang if the market perceives the selling as open-ended.
- Despite strong analyst sentiment, continued insider selling may eventually weigh on the stock if fundamentals weaken.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001958244-26-000593 |
| Document: 0001958244-26-000593-index.html | 0001958244-26-000593 |
| Document: 0001958244-26-000593.txt | 0001958244-26-000593 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | Insider Cluster | $33.19 $33.08 | ▼ −0.33% | ▲ +0.19% | $34.51 (+3.98%) |
Oct 5, 2026 21d ago | 144 | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $34.51 (+3.45%) |
Oct 5, 2026 22d ago | Insider Cluster | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $34.51 (+3.45%) |
Sep 23, 2026 4w ago | Insider Cluster | $35.19 $35.81 | ▼ −1.76% | ▼ −1.22% | $34.51 (+1.93%) |
Sep 16, 2026 5w ago | Insider Cluster | $36.78 $35.34 | ▼ −3.92% | ▼ −4.04% | $34.51 (−6.17%) |
Sep 11, 2026 6w ago | 144 | $33.44 $35.50 | ▲ +6.16% | ▲ +6.62% | $34.51 (+3.20%) |
Sep 3, 2026 7w ago | Insider Cluster | $32.91 $32.76 | ▲ +0.46% | ▼ −0.09% | $34.51 (−4.86%) |
Sep 2, 2026 7w ago | Insider Cluster | $32.65 $32.91 | ▲ +0.80% | ▲ +1.18% | $34.51 (+5.70%) |
Sep 1, 2026 8w ago | Insider Cluster | $33.42 $32.65 | ▼ −2.30% | ▼ −3.35% | $34.51 (+3.26%) |
Aug 27, 2026 8w ago | Insider Cluster | $33.50 $33.03 | ▼ −1.40% | ▼ −1.10% | $34.51 (+3.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers